Key Takeaways
- Volume-led sequential recovery: QoQ improvement came from higher volumes, but raw material costs stayed firm because the partial duty rollback in late May did not lower global vegetable oil prices.
- Dimer acid remains under siege: Chinese price competition and sticky raw material costs continue to compress the segment, with no near-term government relief on dumping or duties.
- Isostearic acid is the value bet, but validation is slow: The global supply base shrank from four players to three, yet customer approvals are taking longer than the promised 3–6 months, delaying the expected export volume ramp.
- Alternative raw material shows promise: Initial trials on a domestically sourced, lower-cost raw material have been successful; a decision is targeted around November, with full benefit unlikely before Q4.
- What to watch next quarter: Whether isostearic acid export volumes actually begin to inflect, any movement on the government duty representation filed in November 2024, and the final call on the alternative raw material.
Raw Material & Duty Headwinds
- The duty shock still bites: The overnight hike in vegetable oil import duty from 5.5% to 27.5% in September 2024 created a 22.5% procurement cost differential that crushed EBITDA margins from the 15%–17% range to roughly 4%.
- Partial rollback, zero relief: The government rolled back 10 percentage points at end-May 2025, but global vegetable oil prices had stayed elevated through the intervening 6–7 months, so raw material costs did not decline after the rollback.
- No near-term policy fix: The company made a representation to the government in November 2024 on dumping and raw material duties but has heard nothing back; management sees no short-term hope for relief.
- Import dependency persists: India is predominantly dependent on vegetable oil imports, and the Ukraine-Russia war continues to weigh on global prices. The next domestic oilseed season begins only in November.
- Byproduct logistics block arbitrage: Freight costs make direct import of byproducts uneconomical; byproducts produced in India must be sold domestically, and foreign byproducts cannot be brought in.
Jariwala: "I would love 5.5% and start making money like before and have a peace of mind."
Isostearic Acid: The Value Pivot
- Supply-side consolidation: One of the four global manufacturers has stopped production, leaving only Fairchem, Cargill and Oleon. Management is "very hopeful" this tightens the market in their favour.
- Capacity is a fraction of demand: Fairchem's isostearic acid capacity represents hardly 10%–15% of total global demand, based on tentative information from companies under negotiation or where material is under approval.
- Validation is the bottleneck: Customers initially indicated 3–6 months for approvals, but the process is taking much longer. Being an Indian company entering a market with only two incumbents, building trust takes time: internet searches, site visits, sample permissions, sample approval, paperwork, bulk supply, stability validation, then actual consumption.
- The barrier is also the moat: The long, arduous validation cycle creates a high entry barrier. A couple more customer approvals were added this quarter, and export volumes are expected to increase gradually over coming quarters.
- U.S. market is non-negotiable: The company cannot depend on Europe alone for isostearic acid sales; the U.S. is one of the largest markets. Future U.S. business may be affected by tariffs, and what was planned and being explored may get impacted.
- Revenue bump delayed, not cancelled: Management expected the isostearic acid revenue inflection "yesterday," but cannot pressurize customers. Once approvals come, they are expected to arrive simultaneously from multiple buyers.
Jariwala: "It's taking pretty long, much more than what we initially expected... And the chances are that we being an Indian Company coming for the first time in the market and only 2 other companies doing, it takes time for them to build a trust in us."
Alternative Raw Material Initiative
- Domestic, cheaper, encouraging: Initial trial runs using an alternative raw material that is not a vegetable oil byproduct have been fairly successful. The material will be fully sourced domestically and at a lower cost than the current feedstock.
- November decision point: The company expects to be through the full evaluation by November. A decision to switch will be taken after due consideration, meaning the entire Q3 may not capture the positive impact.
- Strategic intent: The move aims to reduce import dependence and structurally lower raw material costs, offering a margin recovery path independent of government duty action.
Product Mix & Segment Dynamics
| Product | Share & Trend | Commentary |
|---|---|---|
| Linoleic acid | ~40% of sales, stable | Company expects to maintain this level; no growth rate disclosed. |
| Dimer acid | Part of the 70%–75% prime product mix | Faces aggressive Chinese price competition with no corresponding raw material cost relief; the company wants to stay in the business. |
| Isostearic acid | Part of the 70%–75% prime product mix | Not a byproduct of linoleic acid; made from monobasic acid. More dimer acid production accompanies more isostearic acid. |
- Mix stability with internal rotation: The combined share of the three prime products has held at 70%–75% of sales for many quarters, though individual product shares vary quarter to quarter.
- Value-over-volume logic: Selling more isostearic acid at the same raw material processing level can increase the top line even at 70% capacity utilization.
- Tocopherol/sterol project scrapped: The separate stream project discussed three years ago is now completely off because output was destined for the U.S. market.
Margin & Competitive Position
- Cost advantage exists but is swamped by duty: Manufacturing cost is low, but the 36% tariff differential is too large a gap to overcome through operational efficiency alone.
- Isostearic acid alone cannot fix margins: Management pushed back on the idea that increasing isostearic acid share could lift company-level EBITDA margins from 4% toward 20%+; the recovery has to be gradual and duty-dependent.
- No margin forecast possible: Management declined to give EBITDA margin guidance for FY27, citing unresolved U.S. duty issues and the 51% tariff environment as factors that make prediction impossible.
- EBITDA margin is the right metric: When asked whether EBITDA per ton or EBITDA margin is the correct lens, management affirmed EBITDA margin as a percentage of sales.
Jariwala: "Whatever all the chemical companies are facing, we are facing the same music. In API also the way pharma companies are facing. We are facing the same thing."
Strategic Posture
- Wait, don't react: Management's stated approach is to remain calm and avoid knee-jerk actions, betting that the current situation will not last forever and that long-term confidence in the business model is warranted.
- Inorganic growth sidestepped: When an analyst suggested inorganic growth could accelerate the pace and ease margin pressure given 2.5 difficult years, management did not engage with the suggestion, instead reiterating the isostearic acid value-unlock thesis.
- New product on hold: A new product for which 40,000 tons of capacity is earmarked will take time; the priority is stabilizing current production and resolving current issues first.
- Information asymmetry defended: Management declined to disclose linoleic acid pricing trends, citing competitive sensitivity and the presence of competitors on the call.
Jariwala: "Only thing is we have to wait for the time. We have to rather than taking any knee-jerk action, we have to remain calm and remain in the business."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Isostearic acid export volumes | Increase gradually over coming quarters | Ongoing, no quantified target |
| Alternative raw material decision | Decision on adoption after trial evaluation | Around November 2025 |
| New raw material cost benefit | Lower-cost domestic sourcing to ease margin pressure | Partial impact possible in Q4 FY26 |
| FY26 environment | Year expected to remain competitive and challenging | Full FY26 |
| Government duty representation | Filed November 2024; no response received | No near-term relief expected |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Revenue | ₹100 cr at ~70% capacity utilization |
| EBITDA margin | 3.97%, down from 15–17% before the duty hike |
| Sales mix (3 prime products) | 70–75% of total sales |
| Linoleic acid share | ~40% of total sales |
| Dimer acid share | ~25% of total sales |
| Isostearic acid share | ~6–7% of total sales |
| Material processed | 11,699 MT |
| Material sold | 13,662 MT |
| Capacity utilization | ~70% |
| Installed throughput capacity | 120,000 MT per annum, of which 40,000 MT earmarked for new products |
| Dimer acid price | <₹1,45,000/MT, down ~20% from ₹1,80,000/MT 24 months ago |
| US exposure | <2% of sales, vs ~3% last year |
| Isostearic acid customer approvals | ~18 cumulative, a couple added this quarter |
| Isostearic acid export reach | 7–8 countries |
| Raw material duty differential | 22.5% (vegetable oil duty 27.5% vs dimer import duty 7.5%) |